The FDA approved a proximal hypoglossal nerve stimulation device (aura6000 system) for adults with moderate to severe ...
Hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning ...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug ...
Ryan Hatch has spent his entire life struggling to breathe. “My whole life, I have had trouble breathing through my nose, and ...
Introduction Obstructive sleep apnea (OSA) is characterized by a chronic and progressive disorder that is associated with cardiovascular diseases. Objective To correlate the apnea-hypopnea index (AHI) ...
(“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health ...
More than 80% of patients implanted with a transvenous phrenic nerve stimulation device for central sleep apnea had at least ...
7dOpinion
The Cure for Snoring
Regular snoring becomes more likely as you age. For me, the condition seems to have emerged about five years ago, in my early ...
Morning Overview on MSN
Trial: Sulthiame pill cut sleep apnea breathing interruptions by 50%
A once-daily pill called sulthiame cut breathing interruptions during sleep by up to 47 percent in adults with obstructive ...
Researchers conduct the first meta-analysis comparing hypnotics in OSA patients, finding most are safe but flagging temazepam ...
Chronic obstructive pulmonary disease, commonly called COPD, is a long-term lung condition that makes breathing difficult. It ...
Morning Overview on MSN
Repurposed drug cut sleep apnea events by up to 50% in trial
A repurposed epilepsy drug called sultiame cut breathing interruptions during sleep by up to 50% in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results